| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.29B | 61.01B | 59.53B | 56.50B | 53.17B | 52.71B |
| Gross Profit | 20.11B | 19.73B | 19.04B | 17.98B | 16.73B | 15.99B |
| EBITDA | 7.26B | 6.90B | 6.64B | 6.17B | 5.80B | 4.96B |
| Net Income | 2.47B | 2.17B | 2.10B | 1.92B | 1.88B | 1.11B |
Balance Sheet | ||||||
| Total Assets | 40.45B | 40.88B | 38.98B | 38.15B | 36.61B | 35.87B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 2.11B | 1.95B | 1.93B | 2.44B | 1.94B |
| Total Debt | 19.52B | 19.18B | 18.17B | 17.61B | 16.55B | 16.61B |
| Total Liabilities | 29.25B | 29.61B | 27.36B | 26.69B | 24.88B | 24.75B |
| Stockholders Equity | 11.03B | 11.09B | 11.46B | 11.30B | 11.57B | 10.99B |
Cash Flow | ||||||
| Free Cash Flow | 3.89B | 3.60B | 3.58B | 3.18B | 3.65B | 4.03B |
| Operating Cash Flow | 5.86B | 5.80B | 5.65B | 4.75B | 4.83B | 5.19B |
| Investing Cash Flow | -2.04B | -2.02B | -1.84B | -2.37B | -1.27B | -1.38B |
| Financing Cash Flow | -4.15B | -3.82B | -3.93B | -2.75B | -3.25B | -3.28B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $72.44B | 29.32 | 21.51% | 1.49% | 4.21% | 14.03% | |
78 Outperform | C$20.12B | 20.23 | 14.48% | 1.50% | 3.71% | 12.40% | |
72 Outperform | C$33.11B | 32.95 | 26.36% | 1.21% | 4.15% | 149.50% | |
70 Outperform | C$11.24B | 16.30 | 12.97% | 1.64% | 1.96% | 9.26% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | C$2.19B | 15.82 | 18.55% | 3.33% | 3.04% | 4.17% | |
61 Neutral | C$13.83B | -95.78 | -1.32% | 1.99% | 5.37% | -135.85% |
Loblaw Companies reported a 4.6% revenue growth in the third quarter of 2025, driven by increased customer engagement and new store openings. The company’s focus on value offerings and loyalty rewards contributed to higher sales in both food and drug retail segments. Loblaw’s strategic expansion includes opening 76 new stores and 100 new pharmacy clinics by the end of the year, enhancing its market presence and providing affordable groceries and healthcare to underserved communities across Canada. The company also completed a four-for-one stock split, reflecting its strong financial performance and commitment to future growth.
The most recent analyst rating on (TSE:L) stock is a Buy with a C$67.00 price target. To see the full list of analyst forecasts on Loblaw Companies stock, see the TSE:L Stock Forecast page.
Loblaw Companies Limited has completed a four-for-one stock split of its common shares, effective as of August 19, 2025. This move, executed through a stock dividend, is expected to enhance the liquidity of Loblaw’s shares and potentially broaden its investor base, reflecting the company’s strategic efforts to strengthen its market position.
The most recent analyst rating on (TSE:L) stock is a Buy with a C$261.00 price target. To see the full list of analyst forecasts on Loblaw Companies stock, see the TSE:L Stock Forecast page.